ArticleClinical epigenetics2026
An epigenomic investigation of atrial fibrillation in a matched left and right atrial human cohort.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As the most prevalent cardiac arrhythmia, atrial fibrillation is an important contributor to cardiovascular morbidity and mortality. Human population findings increasingly support its complex genetic architecture, with most genetic association signals for atrial fibrillation found in the non-coding genome. In this study, we integrated genome-wide histone modification, gene expression and DNA methylation levels in a paired left and right atrial cohort comprising permanent atrial fibrillation patients and sinus rhythm controls. First, we first identified epigenomic regions enriched in histone H3 lysine 27 acetylation (H3K27ac) across left and right atria from patients and controls, and associated them with differentially expressed genes to derive a set of dysregulated candidate loci-including NPPB and SCX. Second, by incorporating an independent replication cohort, we were able to validate gene expression and epigenomic differences for a subset of these candidate loci. Third, we profiled base-resolution DNA methylation levels and identified differentially-methylated regions (DMRs) between atrial fibrillation and sinus rhythm samples. Integration of these data with histone modification levels and gene expression allowed us to propose epigenetic mechanisms underlying transcriptomic and epigenomic changes across dysregulated loci, such as disruption of transcription factor binding by DNA methylation at the LRRC4B locus. The data and analyses we report constitute a systematic investigation of gene regulatory alterations across the left and right atria in permanent atrial fibrillation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.